Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

MOVE

Movano Inc

May 01 • 04:00PM ET

0.4867

Dollar change +0.0417
Percentage change 9.37	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.65	Insider Own	63.00%	Shs Outstand	55.85M	Perf Week	-2.46%
Market Cap	47.83M	Forward P/E	-	EPS next Y	-	Insider Trans	0.52%	Shs Float	36.36M	Perf Month	1.61%
Income	-29.28M	PEG	-	EPS next Q	-	Inst Own	9.39%	Short Float	0.63%	Perf Quarter	-20.99%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	3.94%	Short Ratio	1.00	Perf Half Y	-48.22%
Book/sh	0.06	P/B	7.88	EPS next Y	-	ROA	-258.41%	Short Interest	0.23M	Perf Year	-51.33%
Cash/sh	0.06	P/C	7.82	EPS next 5Y	-	ROE	-515.36%	52W Range	0.37 - 1.50	Perf YTD	-37.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.70%	ROI	-840.50%	52W High	-67.55%	Beta	0.19
Dividend TTM	-	Quick Ratio	1.19	Sales past 5Y	0.00%	Gross Margin	-	52W Low	31.54%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	1.44	EPS Y/Y TTM	29.59%	Oper. Margin	0.00%	RSI (14)	49.31	Volatility	8.50% 10.34%
Employees	30	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	52.56%	Payout	-	Rel Volume	0.07	Prev Close	0.44
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Apr 04 AMC	Avg Volume	229.16K	Price	0.49
SMA20	-2.89%	SMA50	-4.01%	SMA200	-41.84%	Trades		Volume	14,969	Change	9.37%

Apr-05-24 08:00AM	Movano Health Closes $24 Million Private Placement (PR Newswire) +8.07%
Apr-04-24 08:52PM	MOVE Stock Earnings: Movano Reported Results for Q4 2023 (InvestorPlace)
04:30PM	Movano Health Reports 2023 Financial Results and Provides Business Update (PR Newswire)
Apr-03-24 07:00AM	BestGrowthStocks.Com Issues Comprehensive Evaluation of Movano Inc. (News Direct) +8.56%
Apr-02-24 05:01PM	Movano Health Announces $24 Million Private Placement (PR Newswire) +8.86%
05:00PM	Loading…
05:00PM	Movano Health Secures Strategic Investment from Tier-One Multi-Billion Dollar Medical Device Company (PR Newswire)
04:05PM	Movano Health to Report Fourth Quarter 2023 Financial Results on Thursday, April 4, 2024 (PR Newswire)
Mar-14-24 06:31PM	Evie Ring's Pulse Oximeter Exceeds FDA Accuracy Guidelines in Movano Health's Second Hypoxia Trial (PR Newswire)
Jan-22-24 08:00AM	Movano Health Announces Evie Rings Now Shipping (PR Newswire)
Jan-09-24 08:00AM	Movano Health and ams OSRAM Collaborate to Deliver Accurate Lifestyle Monitoring Solutions for Women (PR Newswire) -7.20%
Jan-08-24 07:00AM	Evie, the First Women-Focused Health Ring, Takes 'Smart' to a New Level (PR Newswire) +5.00%
Dec-18-23 08:00AM	Movano Health Announces HSA/FSA Eligibility for its Women First Wearable, The Evie Ring (PR Newswire)
Dec-12-23 12:00PM	Movano Health Announces Blood Pressure Partnership Forum Following Significant Response to Groundbreaking Accuracy Achievement (PR Newswire)
Dec-05-23 08:00AM	Movano Health's Women-First Wearable, the Evie Ring, Receives 2024 CES Innovation Award (PR Newswire)
Nov-29-23 08:00AM	Movano Health Announces Over $1M Black Friday Holiday Launch Results for the Evie Ring as well as Cuffless Blood Pressure Milestone Achievement (PR Newswire)
08:00AM	Loading…
Nov-20-23 08:00AM	Evie, the Smart Ring for Women from Movano Health, Available for Order Today (PR Newswire)
Nov-17-23 10:09AM	Movano Health Announces Closing of $4.1 Million Public Offering Including Full Exercise of Over-Allotment Option (PR Newswire)
Nov-16-23 09:45AM	Movano Inc. (NASDAQ:MOVE) Q3 2023 Earnings Call Transcript (Insider Monkey) +6.97%
Nov-15-23 06:02AM	Movano Health Provides Business Update and Reports Third Quarter 2023 Financial Results (PR Newswire) -12.10%
06:00AM	Movano Health Prices $3.6 Million Public Offering (PR Newswire)
Nov-14-23 04:15PM	Movano Inc. to Report Third Quarter 2023 Financial Results on Wednesday, November 15, 2023 (PR Newswire)
04:06PM	Movano Health Announces Proposed Public Offering (PR Newswire)
Nov-03-23 04:05PM	Movano Inc. to Report Third Quarter 2023 Financial Results Tuesday, November 14, 2023 (PR Newswire) -6.11%
Oct-31-23 08:00AM	Movano Health's Proprietary Chip and Prototype Achieves Accuracy Commensurate with the FDA's Requirements for Blood Pressure Monitoring (PR Newswire) +9.57%
Oct-30-23 08:00AM	Movano Health to Launch the Evie Ring on November 20 (PR Newswire) +20.51%
Sep-12-23 09:00AM	Evie Ring Welcomes Cardiologist and Stanford University Associate Professor Dr. Fátima Rodriguez to its Medical Advisory Board (PR Newswire)
Aug-30-23 09:00AM	Movano Health, Maker of the Evie Ring, Selects Jay Group as its Fulfillment Provider in Preparation for its Commercial Launch (PR Newswire)
Aug-14-23 04:05PM	Movano Health Provides Business Update and Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-10-23 09:00AM	Evie Ring Establishes Medical Advisory Board Furthering its Commitment to Bringing a Medical-Grade Wearable to Women (PR Newswire)
Aug-08-23 04:30PM	Movano Inc. to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 (PR Newswire)
09:00AM	Loading…
Aug-03-23 09:00AM	Movano Health Achieves Major Milestone with First FDA Filing for Evie Ring's Pulse Oximeter (PR Newswire)
Jun-21-23 10:49AM	Stock market's fear gauge prices out U.S. recession risk: JPMorgan analyst (Yahoo Finance Video) -11.53%
Jun-15-23 04:05PM	Movano Health Announces Closing of $9.2 Million Public Offering Including Full Exercise of Over-Allotment Option (PR Newswire)
Jun-13-23 08:00AM	Movano Health Prices $8.0 Million Public Offering (PR Newswire) -13.04%
Jun-12-23 04:05PM	Movano Health Announces Proposed Public Offering (PR Newswire)
May-15-23 08:30AM	Movano Health Provides Business Update and Reports First Quarter 2023 Financial Results (PR Newswire) -8.13%
Apr-24-23 09:00AM	Movano Inc. to Report First Quarter 2023 Financial Results on Monday, May 15, 2023 (PR Newswire)
Mar-20-23 08:30AM	Movano Health Provides Business Update and Reports Fourth Quarter 2022 Financial Results (PR Newswire)
Mar-14-23 09:00AM	Movano Health Awarded Three New Core Patents Validating its Cutting-Edge Approach to Radio Frequency-Enabled Glucose and Blood Pressure Monitoring (PR Newswire)
Mar-07-23 09:00AM	What Women Want: Accuracy is Critical to Future Wearable Use (PR Newswire)
Feb-23-23 09:00AM	Movano Inc. to Report Fourth Quarter 2022 Financial Results on Monday, March 20, 2023 (PR Newswire)
Feb-17-23 06:27AM	Daily Vickers Top Buyers & Sellers for 02/17/2023 (Argus Research)
Feb-06-23 09:00AM	Movano Health Completes $7.5 Million Public Offering (PR Newswire)
Jan-27-23 08:00AM	Movano Health Prices $6.5 Million Public Offering (PR Newswire) -6.37%
Jan-26-23 04:03PM	Movano Health Announces Proposed Public Offering (PR Newswire) -10.29%
Jan-17-23 09:00AM	Movano Health's Evie Ring Wins 10 "Best of CES 2023" Awards (PR Newswire) -9.76%
Dec-28-22 09:20AM	Movano Health seeks FDA approval for smart ring for women (American City Business Journals)
07:00AM	Movano Health Unveils Evie: First Medical Grade Smart Ring Designed Uniquely for Women (PR Newswire)
Dec-14-22 09:00AM	Movano Health On Track to File First FDA Submission for its Smart Ring's SpO2 and Heart Rate Data Following Successful Pivotal Hypoxia Trial (PR Newswire)
Dec-13-22 09:00AM	Movano Health Announces Launch of Smart Ring Beta Program with Novant Health (PR Newswire) +9.33%
Nov-16-22 09:00AM	Movano Health to Participate in Bernstein CGM Disruptors Conference, BTIG Digital Health Forum and Benchmark Discovery Conference (PR Newswire)
Nov-14-22 04:30PM	Movano Health Provides Business Update and Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-01-22 04:30PM	Movano Inc. to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 (PR Newswire)
Aug-15-22 04:30PM	Movano Inc. Provides Business Update and Reports Second Quarter 2022 Financial Results (PR Newswire)
04:30PM	Movano Announces Beta Program with Stanford University to Advance the Development of Comprehensive Health Data Monitoring for its Wearable Ring Solution (PR Newswire)
Aug-11-22 09:00AM	Movano Expands Go-To-Market Team with Vice President of UX and UI and Vice President of Digital Marketing and Growth (PR Newswire)
Aug-09-22 09:00AM	Movano to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022 (PR Newswire)
09:00AM	Movano Ring Exceeds Accuracy Targets for SpO2 and Heart Rate Monitoring in Initial Hypoxia Study; Company Eyes FDA Submission (PR Newswire)
Jul-20-22 07:51AM	We're Keeping An Eye On Movano's (NASDAQ:MOVE) Cash Burn Rate (Simply Wall St.)
May-12-22 04:30PM	Movano Successfully Completes Functional Testing of Smallest Ever Custom mmWave Sensor Designed for Non-Invasive Glucose and Cuffless Blood Pressure Monitoring (PR Newswire) -5.61%
04:30PM	Movano Inc. Provides Business Update and Reports First Quarter 2022 Financial Results (PR Newswire)
May-03-22 09:00AM	Movano Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation (PR Newswire)
Apr-28-22 09:50AM	Market check: Stocks climb, shaking off choppy sell-off earlier (Yahoo Finance Video)
Apr-22-22 04:30PM	Movano to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022 (PR Newswire)
Apr-18-22 09:00AM	Movano Welcomes Nan Kirsten Forte, a Pioneer and Innovator in Digital Health, as Its Newest Board Member (PR Newswire)
09:00AM	Movano Hires Chief Marketing Officer to Implement Its Multi-Channel Marketing Strategy for the Movano Ring and Future Medical Devices (PR Newswire)
Mar-24-22 04:30PM	Movano Inc. Provides Business Update and Reports Fourth Quarter 2021 Financial Results (PR Newswire)
Mar-10-22 04:00PM	Movano to Report Fourth Quarter 2021 Financial Results on Thursday, March 24, 2022 (PR Newswire)
Feb-17-22 09:00AM	Movano Completes its Second Glucose Pilot Study (PR Newswire)
Feb-15-22 09:00AM	Movano Announces Two Key Hires to Further Its Go-To-Market Strategy for the Movano Ring and Future Medical Devices (PR Newswire) +15.38%
Feb-10-22 09:15AM	We're Hopeful That Movano (NASDAQ:MOVE) Will Use Its Cash Wisely (Simply Wall St.) -5.66%
Feb-07-22 09:00AM	Movano to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (PR Newswire)
Jan-10-22 09:00AM	Movano to Participate in 24th Annual Needham Virtual Growth Conference (PR Newswire)
Jan-07-22 12:45PM	You Can Fill Up A Bathtub With Just A Voice Command Now (TheStreet.com)
Jan-03-22 09:00AM	Movano Completes Blood Pressure Study with 110 Participants (PR Newswire)
Dec-27-21 07:00AM	Movano Unveils Smart Ring Designed for Women Seeking More Approachable Health Insights (PR Newswire)
Nov-19-21 09:04AM	5 Penny Stocks Insiders Are Buying (Benzinga) -6.78%
Nov-11-21 04:30PM	Movano Inc. Provides Business Update and Reports Third Quarter 2021 Financial Results (PR Newswire)
Nov-09-21 04:30PM	Movano Inc. to Participate in Bernstein CGM Disruptors Conference on Friday, November 19, 2021 (PR Newswire) -6.39%
Oct-14-21 04:30PM	Movano Inc. to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 (PR Newswire)
Aug-16-21 11:34AM	We Think Movano (NASDAQ:MOVE) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-12-21 04:30PM	Movano Inc. Provides Business Update and Reports Second Quarter 2021 Financial Results (ACCESSWIRE)
Jul-14-21 04:30PM	Movano Inc. to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021 (ACCESSWIRE)
Jul-06-21 09:00AM	Movano Conducts IRB-Approved Clinical Study with Prototype Blood Pressure Device (ACCESSWIRE) -5.37%
Jun-08-21 02:00PM	Movano Inc. Set to Join Russell Microcap Index (ACCESSWIRE)
May-13-21 04:30PM	Movano Inc. Provides Business Update and Reports First Quarter 2021 Financial Results (ACCESSWIRE)
03:15PM	Movano Inc to Host Earnings Call (ACCESSWIRE)
Apr-21-21 04:30PM	Movano Inc. to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021 (ACCESSWIRE)
Mar-25-21 04:30PM	Movano Inc. Appoints Medtech Industry Veteran John Mastrototaro, PhD, as CEO (ACCESSWIRE)
04:05PM	Movano Inc. Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option (ACCESSWIRE)
Mar-23-21 08:00AM	Movano Inc. Prices $42.5 Million Public Offering of Common Stock (ACCESSWIRE)

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Leabman in January 2018 and is headquartered in Pleasanton, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FAIRBAIRN EMILY	Director	Nov 14 '23	Buy	0.85	295,000	250,750	295,000	Nov 15 04:11 PM
Mastrototaro John	Chief Executive Officer	Nov 14 '23	Buy	0.85	12,000	10,200	115,142	Nov 15 04:07 PM
Cogan Jeremy	CFO	Nov 14 '23	Buy	0.85	12,000	10,200	735,649	Nov 15 04:04 PM
FAIRBAIRN EMILY	Director	Jun 13 '23	Buy	1.00	250,000	250,000	528,571	Jun 15 04:04 PM
Cogan Jeremy	CFO	Jun 13 '23	Buy	1.00	35,000	35,000	723,649	Jun 15 04:08 PM
Leabman Michael Aaron	Chief Technology Officer	Jun 13 '23	Buy	1.00	25,000	25,000	53,457	Jun 15 04:07 PM
Mastrototaro John	Chief Executive Officer	Jun 13 '23	Buy	1.00	20,000	20,000	103,142	Jun 15 04:05 PM
Cullinan Brian	Director	Jun 13 '23	Buy	1.00	10,000	10,000	237,070	Jun 15 04:02 PM

Open in Screener

INAB

IN8bio Inc

May 01 • 04:00PM ET

1.04

Dollar change +0.02
Percentage change 1.96	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-1.01	Insider Own	32.38%	Shs Outstand	43.29M	Perf Week	-1.89%
Market Cap	45.02M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	0.00%	Shs Float	29.27M	Perf Month	-5.45%
Income	-30.01M	PEG	-	EPS next Q	-0.17	Inst Own	27.31%	Short Float	1.75%	Perf Quarter	-20.00%
Sales	0.00M	P/S	-	EPS this Y	36.80%	Inst Trans	-22.50%	Short Ratio	1.50	Perf Half Y	10.64%
Book/sh	0.58	P/B	1.81	EPS next Y	9.41%	ROA	-89.91%	Short Interest	0.51M	Perf Year	-40.23%
Cash/sh	0.49	P/C	2.12	EPS next 5Y	-	ROE	-125.90%	52W Range	0.65 - 3.48	Perf YTD	-24.64%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-50.62%	ROI	-105.97%	52W High	-70.11%	Beta	0.04
Dividend TTM	-	Quick Ratio	4.57	Sales past 5Y	0.00%	Gross Margin	-	52W Low	60.00%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	4.57	EPS Y/Y TTM	25.79%	Oper. Margin	0.00%	RSI (14)	46.07	Volatility	6.46% 9.21%
Employees	31	Debt/Eq	0.20	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.90
Option/Short	No / Yes	LT Debt/Eq	0.14	EPS Q/Q	33.21%	Payout	-	Rel Volume	0.21	Prev Close	1.02
Sales Surprise	-	EPS Surprise	-43.51%	Sales Q/Q	-	Earnings	Mar 14 AMC	Avg Volume	341.05K	Price	1.04
SMA20	-1.28%	SMA50	-7.23%	SMA200	-9.86%	Trades		Volume	73,668	Change	1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Initiated	Laidlaw	Buy	$7.50
Aug-30-22	Initiated	H.C. Wainwright	Buy	$14

Apr-30-24 06:05AM	IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire)
Apr-24-24 08:00AM	IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 04:05PM	IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (GlobeNewswire)
Apr-09-24 04:30PM	IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 (GlobeNewswire)
Mar-14-24 09:54PM	INAB Stock Earnings: IN8bio Misses EPS for Q4 2023 (InvestorPlace) -7.20%
04:00PM	Loading…
04:00PM	IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024 (GlobeNewswire)
Feb-26-24 08:00AM	IN8bio to Present at Upcoming Investor Conferences (Business Wire)
Feb-14-24 08:00AM	IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology (GlobeNewswire) -6.67%
Jan-04-24 08:00AM	IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals (GlobeNewswire) +12.10%
Dec-11-23 04:05PM	IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia (GlobeNewswire) +29.29%
09:00AM	IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement (GlobeNewswire)
Dec-07-23 08:00AM	IN8bio Appoints Dr. Corinne Epperly to Board of Directors (GlobeNewswire) -5.08%
Dec-05-23 08:00AM	IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia (GlobeNewswire)
Nov-20-23 07:00AM	IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma (GlobeNewswire)
07:00AM	Loading…
Nov-10-23 07:00AM	IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting (GlobeNewswire)
Nov-09-23 04:00PM	IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.61%
Nov-06-23 08:00AM	IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-03-23 12:00PM	IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-02-23 09:17AM	IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-01-23 08:00AM	IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-12-23 08:00AM	IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire) -5.00%
Sep-29-23 08:00AM	IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) -6.31%
Sep-26-23 08:00AM	IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City (GlobeNewswire)
Sep-20-23 08:00AM	IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +12.62%
Sep-19-23 08:03AM	IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents (GlobeNewswire) +7.80%
Sep-06-23 08:00AM	IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-15-23 08:00AM	IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference (GlobeNewswire)
Aug-10-23 04:15PM	IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-23 08:00AM	IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility (GlobeNewswire)
08:00AM	Loading…
Jun-05-23 08:00AM	IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting (GlobeNewswire) -13.33%
May-17-23 08:00AM	IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer (GlobeNewswire)
May-12-23 08:00AM	IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.80%
May-02-23 05:08PM	IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting (GlobeNewswire) +21.84%
May-01-23 08:00AM	IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors (GlobeNewswire) +19.18%
Apr-26-23 10:00AM	IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-25-23 08:00AM	IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma (GlobeNewswire) -36.33%
Apr-24-23 08:00AM	IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023 (GlobeNewswire) +185.71%
Apr-17-23 09:00AM	IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023 (GlobeNewswire) +6.61%
Apr-11-23 08:00AM	IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting (GlobeNewswire) +10.66%
Mar-30-23 04:15PM	IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.11%
Mar-16-23 08:00AM	IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023 (GlobeNewswire) -7.52%
Mar-01-23 08:00AM	IN8bio to Present at the Cowen 43rd Annual Healthcare Conference (GlobeNewswire) +5.88%
Feb-23-23 07:00AM	IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue (GlobeNewswire) -9.44%
Feb-21-23 07:00AM	IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-17-23 07:00AM	IN8bio to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference (GlobeNewswire)
Jan-05-23 07:00AM	IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals (GlobeNewswire)
Jan-03-23 07:00AM	IN8bio to Present at Biotech Showcase 2023 in San Francisco (GlobeNewswire)
Dec-12-22 07:00AM	IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100 (GlobeNewswire)
Dec-08-22 07:00AM	IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma (GlobeNewswire) -5.26%
Nov-10-22 07:30AM	IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire) +6.38%
Nov-03-22 09:10AM	IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-01-22 07:30AM	IN8bio to Present at November Investor Conferences (GlobeNewswire)
Sep-27-22 07:30AM	IN8bio to Present at Cantor Oncology & HemOnc Conference (GlobeNewswire)
Sep-15-22 07:30AM	IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400 (GlobeNewswire)
Sep-13-22 07:30AM	IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.98%
Sep-08-22 07:30AM	IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board (GlobeNewswire) +6.58%
Aug-30-22 04:15PM	IN8bio to Present at September Investor and Scientific Conferences (GlobeNewswire) +39.39%
Aug-19-22 09:20AM	IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering (GlobeNewswire)
Aug-16-22 04:15PM	IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Aug-12-22 04:15PM	IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -6.57%
Aug-11-22 10:05PM	IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -10.00%
Jul-27-22 07:00AM	IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients (GlobeNewswire) +9.10%
Jul-21-22 07:00AM	Newly Issued European Patent Broadens IN8bios Drug Resistant Immunotherapy (DRI) Platform (GlobeNewswire)
Jul-12-22 08:00AM	IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development (GlobeNewswire) -5.28%
Jul-10-22 09:12AM	Is IN8bio (NASDAQ:INAB) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-30-22 04:15PM	IN8bio to Present at July Investor and Scientific Conferences (GlobeNewswire) -6.22%
Jun-08-22 08:00AM	IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences (GlobeNewswire)
Jun-06-22 07:00AM	IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022 (GlobeNewswire)
May-17-22 07:00AM	IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell Off-the-Shelf Induced Pluripotent Stem Cell Platform (GlobeNewswire) -11.43%
May-12-22 08:00AM	IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-22 08:00AM	IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting (GlobeNewswire)
May-04-22 08:00AM	IN8bio to Present at May Investor and Scientific Conferences (GlobeNewswire) +8.80%
May-03-22 11:00AM	Bullish IN8bio, Inc. (NASDAQ:INAB) investors are yet to receive a pay off on their US$1.0m bet (Simply Wall St.) +11.11%
Apr-13-22 08:30AM	IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments (GlobeNewswire)
Apr-05-22 04:15PM	IN8bio to Present at April Investor and Scientific Conferences (GlobeNewswire)
Mar-28-22 08:00AM	IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant (GlobeNewswire)
Mar-17-22 04:15PM	IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +9.42%
Mar-04-22 07:00AM	IN8bio to present at March Investor and Scientific Conferences (GlobeNewswire)
Feb-10-22 05:36PM	IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit (GlobeNewswire)
Jan-31-22 12:29PM	We're Not Very Worried About IN8bio's (NASDAQ:INAB) Cash Burn Rate (Simply Wall St.) +12.33%
Jan-10-22 07:00AM	IN8bio to Present at Upcoming January Investor Conferences (GlobeNewswire) +7.35%
Jan-06-22 07:00AM	IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme (GlobeNewswire) +7.11%
Dec-16-21 07:00AM	IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant (GlobeNewswire)
Dec-09-21 04:30PM	IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer (GlobeNewswire) -7.95%
Nov-16-21 07:00AM	IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer (GlobeNewswire)
Nov-11-21 07:00AM	IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors (GlobeNewswire)
Nov-10-21 04:15PM	IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-21 08:00AM	IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO (GlobeNewswire)
Nov-01-21 09:28AM	Possible turnaround for IN8bio, Inc. (NASDAQ:INAB) insiders, still down US$241k after a US$1.0m shopping spree (Simply Wall St.)
Oct-27-21 07:00AM	IN8bios Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme (GlobeNewswire) -7.46%
Oct-04-21 04:15PM	IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021 (GlobeNewswire)
Sep-10-21 04:15PM	IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-30-21 07:00AM	IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-11-21 08:00AM	IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant (GlobeNewswire)
Aug-04-21 08:00AM	IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors (GlobeNewswire)
Jul-30-21 07:00AM	IN8bio Announces Pricing of Initial Public Offering (GlobeNewswire)

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Graff Jeremy R.	Director	Sep 13 '23	Buy	0.95	2,500	2,375	2,500	Sep 15 04:51 PM
McCall Patrick	Chief Financial Officer	Aug 25 '23	Buy	1.03	1,000	1,030	6,263	Aug 28 04:43 PM
Ho William Tai-Wei	President and CEO	Aug 24 '23	Buy	1.05	23,800	24,990	2,339,545	Aug 28 04:42 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

MOVE

Movano Inc

INAB

IN8bio Inc

Upgrade your FINVIZ experience